middle.news
Alterity’s ATH434 Slows Progression in Advanced Multiple System Atrophy
10:22am on Monday 28th of July, 2025 AEST
•
Biotechnology
Read Story
Alterity’s ATH434 Slows Progression in Advanced Multiple System Atrophy
10:22am on Monday 28th of July, 2025 AEST
Key Points
ATH434 reduced disease progression by approximately 50% over 12 months
Stabilization of neurological symptoms observed in 30% of participants
Neuroimaging showed slowed brain atrophy and reduced iron accumulation
ATH434 was well tolerated with no serious adverse events related to treatment
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE